CN103783623B - 一种提供人体活力的中药组方及其制备方法 - Google Patents
一种提供人体活力的中药组方及其制备方法 Download PDFInfo
- Publication number
- CN103783623B CN103783623B CN201410055026.6A CN201410055026A CN103783623B CN 103783623 B CN103783623 B CN 103783623B CN 201410055026 A CN201410055026 A CN 201410055026A CN 103783623 B CN103783623 B CN 103783623B
- Authority
- CN
- China
- Prior art keywords
- extract
- ultrasonic
- prescription
- raw material
- decoction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000000694 effects Effects 0.000 title abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 41
- 241000220317 Rosa Species 0.000 claims abstract description 19
- 238000000605 extraction Methods 0.000 claims abstract description 18
- 241001074093 Echinopsis Species 0.000 claims abstract description 17
- 239000002245 particle Substances 0.000 claims abstract description 15
- 241000722818 Aralia Species 0.000 claims abstract description 10
- 235000012907 honey Nutrition 0.000 claims abstract description 10
- 239000002023 wood Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000002994 raw material Substances 0.000 claims description 19
- 239000012153 distilled water Substances 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 14
- 230000002441 reversible effect Effects 0.000 claims description 14
- 229910001868 water Inorganic materials 0.000 claims description 8
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- 102000011759 adducin Human genes 0.000 claims 2
- 108010076723 adducin Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 14
- 239000000463 material Substances 0.000 abstract description 12
- 210000005036 nerve Anatomy 0.000 abstract description 6
- 230000005284 excitation Effects 0.000 abstract description 5
- 230000002490 cerebral effect Effects 0.000 abstract description 4
- 230000003340 mental effect Effects 0.000 abstract description 4
- 239000005556 hormone Substances 0.000 abstract description 3
- 229940088597 hormone Drugs 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 230000002929 anti-fatigue Effects 0.000 abstract description 2
- 230000003471 anti-radiation Effects 0.000 abstract description 2
- 238000011109 contamination Methods 0.000 abstract description 2
- 239000005445 natural material Substances 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000035622 drinking Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 150000008130 triterpenoid saponins Chemical class 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 4
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Substances CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000010871 livestock manure Substances 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229910052712 strontium Inorganic materials 0.000 description 3
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002428 insect molting hormone Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- YOSRLTNUOCHBEA-UHFFFAOYSA-N (3beta)-28-(beta-D-glucopyranosyloxy)-28-oxoolean-12-en-3-yl beta-D-glucopyranosiduronic acid Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1O YOSRLTNUOCHBEA-UHFFFAOYSA-N 0.000 description 1
- ZGLHBRQAEXKACO-XJRQOBMKSA-N 1alpha,25-dihydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C ZGLHBRQAEXKACO-XJRQOBMKSA-N 0.000 description 1
- KJKIIUAXZGLUND-ICCVIKJNSA-N 25-hydroxyvitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C KJKIIUAXZGLUND-ICCVIKJNSA-N 0.000 description 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229930192360 Chikusetsusaponin Natural products 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241001669595 Fonsecaea compacta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 229930191515 Pollenin Natural products 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000010183 Thymus Hyperplasia Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- HZWXJJCSDBQVLF-UHFFFAOYSA-N acetoxysulfonic acid Chemical compound CC(=O)OS(O)(=O)=O HZWXJJCSDBQVLF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000035603 choleresis Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种提高人体活力的中药组方及其制备方法,其配方以重量份计,包含以下成份:楤木5份、漏芦10份、糖玫瑰3份和蜂蜜20份。本发明可制备出活力组方饮品和活力组方颗粒两种产品,符合不同情况的需要。本发明选用天然原料无污染的太白山中“愡木﹑漏芦﹑玫瑰”等药材,经过独特的提取工艺将漏芦中蜕皮激素、玫瑰中玫瑰油等有效成分提取出来组成组方,长期饮用无毒副作用,是一种提神抗疲劳、强壮、延寿、抗放射、激活大脑神经、继而达到使人精神兴奋、感到全身充满活力的中药提取物产品。
Description
技术领域
本发明涉及一种提高人体活力的中药组方及其制备方法,属于中药提取物组方领域。
背景技术
生命的基本结构是蛋白质,基本标志是新陈代谢与兴奋性。生命是蛋白质的存在形式,基本因素在于它和周围自然界的新陈代谢,蛋白质是核酸与蛋白质为主要成分的复合体。新陈代谢是机体与周围环境之间进行的物质交换过程。新陈代谢是由两个对立统一、互相依存的过程组成的。这就是同化(合成)作用和异化(分解)作用。同化是机体经外界环境中摄取营养物质,合成自身成分,并贮存能量的过程;异化是机体分解自身成分,释放其中热量,供生命活动的需要,最后将废物排出体外的过程。物质合成与分解称物质代谢。伴随物质代谢而出现的能量的释放、转化、利用过程是能量代谢。机体通过新陈代谢不断的与外界环境进行物质交换和自我更新,这是生命的基本因素。机体、合成、生长、发育、繁殖、进化等生命现象,无不以新陈代谢为基础。新陈代谢停止,生命也即告终。兴奋性是指机体生命结构能对周围环境变化发生反应的能力。兴奋性由两个对立统一,互相依存的过程组成,即兴奋与抑制。兴奋指组织由相对静止变为活动状态,或由弱活动变为强活动。抑制则相反,是指组织由相对活动变成相对静止,或由强活动变成弱活动。整个机体的兴奋与抑制有它的特有表现特征,而各个组织的兴奋与抑制也有它的表现特征。如肌肉兴奋就是运动,抑制则停止。腺体兴奋就是分泌,抑制则是分泌停止或弱缓。人的机体依靠整体性及机体活动可调节性(包括神经调节、体液调节、各组织调节)二个机理达到整体统一的整体新陈代谢。
人类生命现象包括成形、出生、生长、发育、成熟、繁衍、衰老、死亡几个部分。衰老是每个人都必须经历的过程,衰老会带来一系列问题及并发症,具体表现在:1.健忘、易疲劳、对外界反应迟钝,动作缓慢,早醒或昏睡,喜静不喜动。2.肌肉松弛,皮肤出现深浅、方向不一的负重皱纹,尤以面部为甚。且皮肤枯燥无光泽、色暗,有的出现色素沉着点(老年斑)。3.食欲减少,便秘或者便溏,小便次数多。4.对高温、低温适应能力差,尤为惧冷。5.髪鬚色渐变白,数量渐变稀少,甚至秃顶。眉毛变长(寿眉出现)6.脾性反常,易发燥。7.整体细胞代谢减慢。与蛋白质合成,核酸合成,细胞有丝分裂有关的器官功能,各种酶的活性降低。8.免疫各器官功能降低,血中各免疫细胞活性降低,包括外周血T淋巴细胞、B淋巴细胞的活性降低。免记忆细胞数量、种类、活性等方面的降低。9.蛋白质代谢、脂肪代谢、核酸代谢、微量元素代谢、胆固醇代谢、糖代谢等功能活性下降。10.各器官功能活性下降,各种内分泌液量下降。11.解毒功能下降尤其是对自由基排降能力下降。12.骨质疏松(胶质减少,钙质增多)。13.常患的疾病有,感冒,肺气肿,气管炎,高血压,动脉粥样硬化,糖尿病,心肌供血不良,脑血管意外及血管痉挛,手振颤,细胞癌变,脏器内结石等。
中国中医研究院李春生在人群中做过这样的调查,经常服用传统的具補益物质的人,结果他们的精神状态,抗病能力,及适应能力,动作敏捷度都较不常使用传统補益物质的人均好,且寿命长。
发明内容
本发明所要解决的技术问题是提供一种提高人体活力的中药组方及其制备方法,选用天然物质结合现在研究的抗人体衰老的确切结论而成,长期饮用无毒副作用,是一种提神抗疲劳、强壮、延寿、抗放射、激活大脑神经、继而达到使人精神兴奋、感到全身充满活力的中药提取物产品。
本发明解决上述技术问题的技术方案如下:一种提高人体活力的中药组方,以重量份计,包含以下成份:楤木5份、漏芦10份、糖玫瑰3份和蜂蜜20份。
楤木(CortexAraliae):
主含成份:三萜皂甙为楤木皂甙A,B,C。
主成分作用:齐墩果酸:清热,消炎,抑菌,强心,利尿,抑制s-180瘤株生,降低谷一丙转氯酶及退黄疸等作用。
三萜皂甙是人参抗人衰老活性物质中一种。(《中草药成分化学》高校教材)
作用:1.水浸液使人中枢神经系统兴奋。增强咖啡因,士的宁的中枢神经兴奋作用。对抗巴比妥类中枢神经有抑制作用。2.提高人体的活动能力3.小量醇浸液对人心脏有强心作用。
漏芦(RadixRhapontici):
本配方中漏芦苏联已产出多种以漏芦为主料的抗人体衰老的食用产品。
主含成份:脱皮激素,脱皮甾酮。
作用:1.脱皮激素:使人适应原样作用。提高人的工作能力及对高温的适应性,在贫血情况下刺激人体红细胞生成,从而纠正人体贫血状况。促进人体蛋白质和核酸的合成,其强度在同化激素之上,且无雄性样作用。2.脱皮甾酮:逆转因高血糖素引起的高血糖症。抑制肝胆固醇合成。提高正常及免疫受抑人体外周血T淋巴细胞数量和比值。预防环磷酰胺抑制免疫功能。水煎剂改善食饵性高脂症。降低血中的胆固醇,低密度脂蛋白。降低人动脉粥样硬化病的进程。降低血清中过氧化脂质水平,减少心〃脑〃肾组织中脂褐色素的含量,防止自由基对衰老机体的损害。除去面部老年性沉着。减少血浆和动脉壁血栓素并升高前列腺环素的产生,减弱血小板聚集趋势。(北京中药学院基础部龚树生《祁卅漏芦的抗衰老作用》《中药杂志》1988.1)3.促进人体内蛋白质合成,特别能增进肝脏蛋白质合成,排除体内胆甾醇积累,抑制血糖上升,降低血压。(《中草药成分化学》高校教材)
作用:1.水煎剂对人体革兰氏黄癣菌,紧密着色芽生菌,星形奴卡氏菌等多种皮肤类菌有不同程度的抑制作用。2.苏联研究认为经常服用能使人恢复青春活力。且已制成多种产品供老年人服用。3.《神农本草经》久服轻身益气,耳目聪明,不老延年。(《全国中草药汇编》《祁卅漏芦的抗衰老作用》)
糖玫瑰花:
配方:中糖玫瑰花是我国食品工业一直广泛采用的天然香料。可用糖桂花代替。糖桂花也是我国食品工业一直采用的天然香料。(《食品工业各式点心配方》)
主含成份:玫瑰油与糖。
作用:1.特殊的香气,激动嗅觉神经,进而兴奋中枢神经,大脑神经,达到使人精神兴奋,感到全身充满活力,并引起食欲。2.口服玫瑰可增加胆汁分泌到胆中的作用。并增加胆的排胆汁到肠中的量,故能增加人的消化脂肪功能和人体的解毒作用。
蜂蜜(SugarofApiscerana(mei)):
主含成份:转化糖(葡萄糖与果糖的混合物)花粉粒,泛酸(Pantothenicacid),维生素A,D,E微量元素47种(包括锶)。
作用:烟酸在体内转为烟酰胺nicotinamidum后发挥作用,二者统称为维生素pp,烟酸吸收后转为烟酰胺与核糖,磷酸,腺嘌呤构成辅酶I和辅酶II,是某些脱氧酶的辅助酶,在生物氧化过程中起脱氢加氧的作用,与糖脂肪代谢有密切的关系,大量口服有扩强血管的作用,并降低胆固醇。纠正因缺乏烟酸所致食欲不振,肠炎,腹泻,失眠,感觉异常,皮肤爆裂似鱼鳞之名为糙皮病。
维生素A:1.维持上皮肤组织的完整与健全,参与间质组织之粘多糖合成。纠正缺乏时所致上皮肤细胞腺体分泌物降低的干眼病。角膜角化,皮肤,呼吸道,泌尿上皮均角化的皮肤干燥症。毛囊周围角化,丘疹,粘膜抵抗力降低等。2.参与视紫红色的合成,纠正夜盲症3.促进胸腺增生,增加人体免疫力,还使血液中白细胞逐渐增加,故可预防癌症发生。(《药理学》)
维生素D:是多种抗佝偻病成分的总称,D2又叫骨化醇(Calciferol),D3又叫胆骨化醇(Cholecalciferol)。1.人体吸收后先经肝细胞线粒体的羟化酶作用25—羟维生素D2,再经肾脏羟化形成1、25—二羟维生素D2,它促进小肠黏膜细胞核合成运钙蛋白,运钙及磷,血钙升高促进了骨组织钙化。2.老年人血钙过低引起肌肉抽搐、惊厥称为老年手足抽搐症。D1可使老年手足抽搐症消失。(《药理学》)
维生素E:又名生育酚(Tocopherol):1.男人缺失无生育能力,女人可致先兆流产。2.参与人体固有抗衰老机能的活动。(《药理学》)
花粉:目前公认的一种抗人体衰老成分,有系列化多种抗人体衰老的食用性产品问世,如花粉饮料、花粉素等。花粉中微量元素:锌、铜、锰、钼、锶等人体所需各类微量元素,蜂蜜均含且共含47种元素。其中锶更为重要,可预防老年人因骨质疏松所致骨折。铜可乌发。作用:1.目前公认的抗人体衰老。2.对创面有收缩、营养并促进愈合的作用。3.是润滑性祛痰和缓泻品。
乙醇,作用:1.促使毛细血管灌注量增加,增加食欲。2.小量经常使用能增进血流量改善动脉粥样硬化。3.在体内合成二氧化碳和水,二氧化碳经肺中排出,并兴奋促进人呼吸。
生产前主要原料测试方法:
漏芦:
外观:全根外皮土棕色至暗色,有菱形多数裂隙。
饮法:外皮土棕色,内部黄白色,间有多数暗棕色相隔的空隙。
外观具上述两个特点的是祁卅漏芦。
测试主成分:蜕皮激素、蜕皮甾酮。
主成分测定方法:1.取原料10g加蒸馏水适量,煮沸60分钟,过滤(单层滤纸)弃掉残渣,将滤液水浴蒸干备用。2.取滤液蒸干粉加适量甲醇溶解,单层滤纸过滤。弃残渣后,水溶蒸去甲醇备用。3.取甲醇提取粉加适量乙醚后,反复振摇,静置60分钟,过滤弃去乙醚滤液(含有脂溶性物质)。残渣备用。4.乙醚残渣加氧仿溶解后加硫酸-醋酐溶液后,应显红-紫(兰)-绿色(Liebermann——Burchand反应)。乙醚残渣加氯仿溶解后,加硫酸后,量液面应显兰紫色(Salkowski反应)。
证明含:基脱皮甾酮
楤木:
测试成分:三萜皂甙、齐墩果酸。
成分测量方法:1.取原料5g,加适量水(蒸馏水),煮沸60分钟后,放冷,加适量乙醇,振摇均匀静置60分钟过滤,弃去残渣。滤液水溶蒸干,备用。2.加乙醚适量,振摇,静置,滤去乙醚液,残渣备用。(乙醚脱色)3.乙醚残渣加醋酐溶解后,再加浓硫酸-醋酐试液(硫酸——醋酐试液),
若显示红-紫(兰)色,则为三萜皂甙;若显示红-兰(绿)-绿色,则为甾体三萜皂甙。
乙醇(体积分数95%):
测试成分:乙醇。
测试方法:将波表比重计(乙醇比重计)放于酒中,观察比重计上的刻度,即可。另外也可《中华人名共和国药典》一部,按乙醇项去测量。
本发明的提高人体活力的中药组方可制成饮品和颗粒两种模式,具体制备方法如下:一种提高人体活力的中药组方饮品的制备方法,包括以下步骤:
(1)选取5重量份的楤木、10重量份的漏芦和3重量份的糖玫瑰,经粉碎过50目筛备用;
(2)将步骤(1)中过筛后的原料混合在一起,加入原料总重量10倍的蒸馏水,超声逆回流提取60min,提取液倒出静置(放凉),向所剩的药渣中再加入原料总重量10倍的蒸馏水,超声逆回流提取60min,提取液倒出静置(放凉),所剩的药渣备用;将得到的两份提取液混合在一起,得到水提取液;
(3)向步骤(2)蒸馏水提取完的药渣中加入原料总重量10倍的体积分数为95%的乙醇,超声逆回流提取60min,提取液倒出静置(放凉),得到醇提取液;
(4)将步骤(2)得到的水提取液、步骤(3)得到的醇提取液混合在一起,静置48小时;
(5)再加入20重量份的蜂蜜,于超声逆回流设备中超声逆回流超声提取30min,得到最终的提取液;
(6)将步骤(5)得到的提取液以单层过滤布过滤,再用饮品罐装机进行加工,得到所述提高人体活力的中药组方饮品。
一种提高人体活力的中药组方颗粒的制备方法,包括以下步骤:
(1)选取5重量份的楤木、10重量份的漏芦和3重量份的糖玫瑰,经粉碎过50目筛备用;
(2)将步骤(1)中过筛后的原料混合在一起,加入20重量份的蜂蜜,再加入原料总重量20倍的蒸馏水,超声逆回流提取60min,提取液倒出静置(放凉),向所剩的药渣中再加入原料总重量20倍的蒸馏水,超声逆回流提取60min,提取液倒出静置(放凉),所剩的药渣备用;将得到的两份提取液混合在一起,得到水提取液;
(3)向步骤(2)蒸馏水提取完的药渣中加入原料总重量20倍的体积分数为95%的乙醇,超声逆回流提取60min,提取液倒出静置(放凉),得到醇提取液;
(4)将步骤(2)得到的水提取液、步骤(3)得到的醇提取液混合在一起,静置48小时;
(5)将步骤(4)混合的提取液进行过滤,得到过滤液体;
(6)将步骤(5)得到的过滤液体在真空浓缩器中回收乙醇,浓缩成缩膏,再在微波真空干燥箱中干燥,粉碎过40~60目筛,获得颗粒粉末,再用颗粒罐装机进行加工,得到所述提高人体活力的中药组方颗粒。
本发明是在近几年至以后社会老龄化的现状下发明的产品。现在人群工作压力大,电脑辐射强,不管少年,青年,老年及学生共同存在的一个问题是:记忆减退,学习工作休息,疲劳状态不得消失。本配方专解决以上问题,配方中玫瑰的香气,激活大脑神经,继而达到使人精神兴奋,感到全身充满活力,引起食欲,可增强胆汁分泌到胆中的作用,并增强胆的排胆汁到肠中的作用,既能增加人的消化脂肪功能和人体的解毒作用。
本发明选用天然原料无污染的太白山中“愡木﹑漏芦﹑玫瑰”等药材,经过独特的提取工艺将漏芦中蜕皮激素、玫瑰中玫瑰油等有效成分提取出来组成组方,达到如下目的:激活增加人体免疫抗病能力(漏芦中的脱皮甾酮发挥作用):激活T淋巴细胞,产生多种淋巴因子来消灭抗原,激活B淋巴细胞,转变成浆细胞,合成各种具特异功能的免疫球蛋白(補体),发生抗原抗体反应来消灭抗原,因为具有增加蛋白质、核酸合成的作用,又促进B2吸收,因白细胞合成不发生障碍,从而提高人抗病的能力,预防多种传染病的发生,也提高了人的整体调节性;提高人体蛋白质核酸的合成能力:蛋白质、核酸合成能力提高自然而然人体的整体代谢、修复能力提高;提高人体消化吸收能力:新陈代谢所需的各种物质包括能量糖,都必须经消化中获得,消化能力降低,自然人体所需各种营养物就得到的少,反之就得到的多,从而供给了人体进行新陈代谢提供了良好的条件;兴奋神经,提高人体适应能力;增加血液循环速度,达到人体新陈代谢废物排出和提高人体御寒能力;它们本身就富含各种人体所需的营养物质,参与人体功能代谢活动;使面皱纹消失,老年斑消失,色泽焕发青春,提高人体反细胞对暂时性缺氧的适应能力。
具体实施方式
以下对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。
实施例1
将药材楤木5kg、漏芦10kg、糖玫瑰3kg分别精选粉碎过50目筛,投入在超声逆回流设备中,加入蒸馏水180kg,超声逆回流提取60min,过滤液体160kg于储存罐中,再在药渣中加入蒸馏水180kg,超声逆回流提取60min,过滤液体170kg于储存罐中(提取水溶性物质)。在药渣中再加入体积分数为95%的乙醇180kg,于超声逆回流设备中超声提取60min,过滤液体180kg于储存罐中(提取乙醇溶解物质)。药渣蒸流回收乙醇,药渣进入发酵后做发酵菌肥使用。
合并提取水溶性物质,提取乙醇溶解物质,共计510kg.于分离器中静置48小时,过滤器中过滤液体500kg.(过滤物10kg,进入药渣发酵做发酵菌肥使用)。过滤液体进入超声逆回流设备中将蜂蜜20kg加入超声逆回流提取30min,于过滤器中过滤液体518kg,(过滤物2kg,进入药渣发酵做发酵菌肥使用)过滤液体518kg,按照饮品制备工艺共制成饮品500ml/瓶,100瓶/袋。
实施例2
将药材楤木5kg、漏芦10kg、糖玫瑰3kg分别精选粉碎过50目筛,加入在超声逆回流设备中,加入蒸馏水360kg,加入蜂蜜20kg。超声逆回流提取60min,过滤液体340kg于储存罐中,在药渣中再加入蒸馏水360kg,超声逆回流提取60min,过滤液体350kg于储存罐中(提取水溶性物质)。在药渣中再加入体积分数为95%的乙醇360kg,于超声逆回流设备中超声提取60min,过滤液体360kg于储存罐中(提取乙醇溶解物质)。药渣蒸流回收乙醇,药渣进入发酵后做发酵菌肥使用。
合并提取水溶性物质,提取乙醇溶解物质,共计1050kg.于分离器中静置48小时,过滤器中过滤液体1030kg。(过滤物20kg,进入药渣发酵做发酵菌肥使用)。过滤液体于真空浓缩器中回收乙醇,浓缩成浓缩膏,于微波真空干燥箱中干燥,粉碎过40~60目筛,获得颗粒粉末5000g,按照颗粒制备工艺配制成颗粒,每颗5g,每袋1000颗。
以上实施例采用的设备是:超声逆回流提取设备、微波真空干燥箱,选择陕西省三原红旗设备厂生产的设备;饮品灌装机、颗粒制备灌装机、粉碎机、过滤器、真空浓缩器,选择浙江温州华美药械设备制造厂生产的设备。
使用效果(临床病例):
1.张某某,男、68岁。2年前患者出现头晕、失眠、记忆力减退、精神恍惚在市人民医院就诊,诊断为“神经衰弱、脑萎缩”应用中西医结合治疗年余,效果不佳。服用活力组方饮品三周后,头晕、失眠症状明显改善,无其它不适。半年后随访,上述症状基本消失。
2.李某某、女、17岁,高中学生。半来前因学习压力较大,出现头痛、头晕、注意力不集中、经常失眠、记忆力减退,学习成绩下降。额面部出现青春痘伴疖肿,便秘等症状。曾在多家医院就诊治疗,症状未见明显好转,经服用活力组方颗粒后,头痛、头晕症状消失,记忆力逐渐回复,青春痘消失,便秘明显改善,学习成绩逐步上升。
3.王某某、男、44岁,1年来出现疲倦乏力、腰腿酸软、烦躁、失眠、须发变白、面部皱纹增多、怕冷、夜尿频多等症状、性功能减退,曾服中药调理,效果不佳。服活力组方饮品一年后,以上症状明显好转。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (2)
1.一种活力组方饮品的制备方法,其特征在于,包括以下步骤:
(1)选取5重量份的楤木、10重量份的漏芦和3重量份的糖玫瑰,经粉碎过50目筛备用;
(2)将步骤(1)中过筛后的原料混合在一起,加入原料总重量10倍的蒸馏水,超声逆回流提取60min,提取液倒出放凉,向所剩的药渣中再加入原料总重量10倍的蒸馏水,超声逆回流提取60min,提取液倒出放凉,所剩的药渣备用;将得到的两份提取液混合在一起,得到水提取液;
(3)向步骤(2)蒸馏水提取完的药渣中加入原料总重量10倍的95%乙醇,超声逆回流提取60min,提取液倒出放凉,得到醇提取液;
(4)将步骤(2)得到的水提取液、步骤(3)得到的醇提取液混合在一起,静置48小时;
(5)再加入20重量份的蜂蜜,于超声逆回流设备中超声逆回流超声提取30min,得到最终的提取液;
(6)将步骤(5)得到的提取液以单层过滤布过滤,再用饮品罐装机进行加工,得到所述活力组方饮品。
2.一种活力组方颗粒的制备方法,其特征在于,包括以下步骤:
(1)选取5重量份的楤木、10重量份的漏芦和3重量份的糖玫瑰,经粉碎过50目筛备用;
(2)将步骤(1)中过筛后的原料混合在一起,加入20重量份的蜂蜜,再加入原料总重量20倍的蒸馏水,超声逆回流提取60min,提取液倒出放凉,向所剩的药渣中再加入原料总重量20倍的蒸馏水,超声逆回流提取60min,提取液倒出放凉,所剩的药渣备用;将得到的两份提取液混合在一起,得到水提取液;
(3)向步骤(2)蒸馏水提取完的药渣中加入原料总重量20倍的95%乙醇,超声逆回流提取60min,提取液倒出放凉,得到醇提取液;
(4)将步骤(2)得到的水提取液、步骤(3)得到的醇提取液混合在一起,静置48小时;
(5)将步骤(4)混合的提取液进行过滤,得到过滤液体;
(6)将步骤(5)得到的过滤液体在真空浓缩器中回收乙醇,浓缩成缩膏,再在微波真空干燥箱中干燥,粉碎过40~60目筛,获得颗粒粉末,再用颗粒罐装机进行加工,得到所述活力组方颗粒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410055026.6A CN103783623B (zh) | 2014-02-18 | 2014-02-18 | 一种提供人体活力的中药组方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410055026.6A CN103783623B (zh) | 2014-02-18 | 2014-02-18 | 一种提供人体活力的中药组方及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103783623A CN103783623A (zh) | 2014-05-14 |
CN103783623B true CN103783623B (zh) | 2016-05-04 |
Family
ID=50660009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410055026.6A Active CN103783623B (zh) | 2014-02-18 | 2014-02-18 | 一种提供人体活力的中药组方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103783623B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105902827A (zh) * | 2016-02-03 | 2016-08-31 | 驻马店市农业科学院 | 提高人体免疫力的中药组合物及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2001095C1 (ru) * | 1993-02-09 | 1993-10-15 | Израиль Ицкович Брехман | Бальзам |
RU2098985C1 (ru) * | 1994-12-14 | 1997-12-20 | Акционерное общество "Бальзам" | Биоактивный препарат "целебный дар алтая" |
RU2113457C1 (ru) * | 1993-05-25 | 1998-06-20 | Акционерное общество открытого типа "Тайга" | Композиция ингредиентов для настойки "таежная" |
CN1900106A (zh) * | 2005-07-20 | 2007-01-24 | 北京凯瑞创新医药科技有限公司 | 一种中药提取物的制备方法和质量控制方法 |
CN1903240A (zh) * | 2006-08-09 | 2007-01-31 | 陈保任 | 草本刺嫩芽的医药用途 |
CN101199668A (zh) * | 2006-12-11 | 2008-06-18 | 孙蓉 | 一种治疗酒精性脂肪肝的中药制剂及其制备方法 |
-
2014
- 2014-02-18 CN CN201410055026.6A patent/CN103783623B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2001095C1 (ru) * | 1993-02-09 | 1993-10-15 | Израиль Ицкович Брехман | Бальзам |
RU2113457C1 (ru) * | 1993-05-25 | 1998-06-20 | Акционерное общество открытого типа "Тайга" | Композиция ингредиентов для настойки "таежная" |
RU2098985C1 (ru) * | 1994-12-14 | 1997-12-20 | Акционерное общество "Бальзам" | Биоактивный препарат "целебный дар алтая" |
CN1900106A (zh) * | 2005-07-20 | 2007-01-24 | 北京凯瑞创新医药科技有限公司 | 一种中药提取物的制备方法和质量控制方法 |
CN1903240A (zh) * | 2006-08-09 | 2007-01-31 | 陈保任 | 草本刺嫩芽的医药用途 |
CN101199668A (zh) * | 2006-12-11 | 2008-06-18 | 孙蓉 | 一种治疗酒精性脂肪肝的中药制剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
漏芦中蜕皮甾酮提取方法研究;陈莉莉,等;《中药材》;20020331;第25卷(第3期);第195-197页 * |
漏芦提取物抗衰老作用的研究;朴龙,等;《时珍国医国药》;20061231;第17卷(第10期);第1918-1919页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103783623A (zh) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103525632B (zh) | 一种保健酒及制备方法 | |
CN102524624B (zh) | 具有改善睡眠作用的蜂产品制品及其制备方法 | |
CN101828714B (zh) | 一种用于延缓衰老的保健食品 | |
CN108236656A (zh) | 一种增强免疫力、养颜美容、滋润女性肾功能的膏滋 | |
CN109247571A (zh) | 一种抗衰防老养生保健食品及其制备方法 | |
CN104403901A (zh) | 一种糯米灵芝保健酒的酿制方法 | |
CN114042126B (zh) | 升清化浊利湿益气减肥降脂中药组合物及其制剂制备方法 | |
CN105925421A (zh) | 一种防治更年期综合征的金花葵保健酒及其制备方法 | |
CN108185441A (zh) | 一种治疗糖尿病的配方食品及其制备方法 | |
CN104352552A (zh) | 一种食品、保健品或药物组合物 | |
CN108066712A (zh) | 一种补气养血中药组合物 | |
CN107912773A (zh) | 一种用于缓解体力疲劳的制剂 | |
CN102512591B (zh) | 一种具有减肥降糖降脂作用的组合物 | |
CN103783623B (zh) | 一种提供人体活力的中药组方及其制备方法 | |
CN103082240B (zh) | 一种胡萝卜参的加工方法 | |
CN104824649B (zh) | 一种保健丸及其制备方法 | |
CN103229872A (zh) | 一种延缓衰老的食品养生茶冲剂 | |
CN103830558B (zh) | 一种抗衰老组合物及其制备方法 | |
CN108633997A (zh) | 一种具有抗疲劳功能的保健羊奶粉及其制备方法 | |
CN100577189C (zh) | 益脂保健组合物胶囊及其制备方法 | |
CN102511868A (zh) | 一种添加维生素的红枣阿胶浓浆 | |
CN106509523A (zh) | 鹿胶饮料 | |
CN101884758B (zh) | 基于治未病和药食同源理论的防治脑血管病的食疗制剂 | |
CN103404667A (zh) | 一种改善营养性贫血的食品养血茶冲剂 | |
CN103202926A (zh) | 一种用于防治心脑血管疾病、延缓衰老的软胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170825 Address after: 725000 Water Exhibition Hall of eco Culture Park, hi tech Industrial Development Zone, Ankang, Shaanxi Patentee after: Shaanxi Shengtai health biotechnology limited liability company Address before: 721004 Baoji City, Shaanxi province Jintai District of Wolong Si Bao Guo Road No. 46 Building 2 unit 2 No. 11 hospital Patentee before: Hu Jianmin |